Neoadjuvant therapy is a type of treatment given before the main treatment for cancer. It might include chemotherapy, radiation, or other medicines. The goal is to shrink the tumor or make it easier to remove during the main treatment.
Every report comes from a Lived member, sent anonymously.
Have you tried Neoadjuvant Therapy for Breast Cancer?
Neoadjuvant therapy is cancer treatment given before the main treatment, which is usually surgery. It is a matter of timing rather than a single kind of treatment: chemotherapy, radiation, hormone therapy, targeted drugs or immunotherapy can all be given this way, alone or in combination. Treatment given after surgery is called adjuvant therapy. Starting with drugs or radiation can shrink a tumor so that it is easier to remove completely, or so that a smaller operation becomes possible. Drug treatments also travel through the bloodstream and can reach cancer cells that may already have spread too thinly to see on scans. A further advantage is that the team can watch how the tumor responds. When the surgeon removes the remaining tissue, a pathologist examines it under a microscope, and how much cancer is left helps guide what happens next.
Neoadjuvant therapy is used mainly for cancers that can potentially be cured with surgery but are large, have reached nearby lymph nodes or sit where a complete operation would be difficult. It is a well-established approach for many breast, rectal, esophageal and lung cancers, and is also used for some other cancers. Whether it fits a particular person depends on the cancer type, its stage, its biology (for example, whether a breast cancer is fueled by hormones, makes too much of a growth protein called HER2, or has neither feature, known as triple-negative) and the person's overall health. For a small, early cancer, going straight to surgery is often the better choice.
The plan is usually made by a team that includes a surgeon, a medical oncologist and often a radiation oncologist. Before treatment begins, imaging and a biopsy confirm the diagnosis and stage. For some cancers, such as breast cancer, a small marker may be placed in the tumor so the surgeon can still find the area if it shrinks a great deal. Chemotherapy and immunotherapy are typically given in cycles, with a treatment period followed by a rest period, often by infusion through a vein, over several weeks to several months depending on the regimen. Some people have a port, a small device placed under the skin, to make repeated infusions easier. Neoadjuvant chemoradiation, common for rectal and esophageal cancers, combines chemotherapy with radiation sessions given on weekdays for about five weeks. Blood tests, exams and repeat scans during treatment check side effects and whether the tumor is responding. Surgery usually follows several weeks after the last treatment, once the body has had time to recover.
Side effects depend on the drugs or radiation used. Fatigue, nausea, mouth sores and hair loss are common with chemotherapy, and radiation tends to cause effects in the area being treated. Many side effects can be prevented or eased, and most settle after treatment ends. Response varies. Many tumors shrink, some only a little, and in some people no invasive cancer is found at all when the tissue is examined after surgery. This is called a pathologic complete response, and it is generally linked with a better outlook, especially in aggressive breast cancer types. Having cancer left over is common and does not mean treatment failed, but it gives useful information: for some breast cancers, people with remaining cancer are offered a different or additional treatment after surgery that lowers the chance of the cancer coming back. In selected people with rectal cancer whose tumor appears to have disappeared after a full course of neoadjuvant treatment, some cancer centers offer close monitoring instead of immediate surgery, an approach often called watch and wait. This requires frequent checkups, and surgery is still done if the cancer regrows.
The benefit depends heavily on the cancer type, so results from one cancer should not be assumed for another. In early breast cancer, a large analysis of randomized trials found that giving the same chemotherapy before rather than after surgery allowed more women to have breast-conserving surgery (65% compared with 49%), with no difference in long-term survival or spread of the cancer. Its main value there is a smaller operation and information about response, not a longer life from the timing alone. In locally advanced rectal cancer, chemoradiation before surgery halved the rate of cancer returning in the pelvis compared with the same treatment after surgery and caused fewer severe side effects, though overall survival was similar. In esophageal cancer, chemoradiation before surgery improved survival compared with surgery alone and made complete removal of the tumor more likely. Newer combinations add immunotherapy to chemotherapy before surgery for some lung cancers and triple-negative breast cancers; trials showed more complete responses and longer time without the cancer returning or worsening. In rectal cancer, giving all chemotherapy and chemoradiation before surgery, known as total neoadjuvant therapy, roughly doubled complete responses and modestly reduced recurrence, but has not been shown to lengthen overall survival. In one trial, about half of patients were able to avoid rectal surgery, though longer follow-up is still being gathered.
Chemotherapy lowers white blood cell counts and makes infections more likely and potentially serious. During treatment, a fever of 100.5°F (38°C) or higher, chills or other signs of infection should be reported to the care team right away, using the number and fever threshold the team provides. Immunotherapy can cause the immune system to inflame healthy organs such as the skin, bowel, lungs or hormone glands, sometimes weeks or months after a dose, so new symptoms are worth reporting even after treatment ends. In a small share of people, the tumor grows during neoadjuvant therapy instead of shrinking. Regular checks are meant to catch this early so the team can switch treatment or move to surgery sooner. In breast cancer, tumors that shrink enough for breast-conserving surgery have a somewhat higher chance of returning in the breast, which is why careful marking of the tumor and radiation afterward matter. Neoadjuvant therapy also means months of treatment before an operation, with time away from work, travel to appointments and costs to plan for. People who hope to have children may want to discuss fertility preservation before chemotherapy begins.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Neoadjuvant Therapy, what's helped you, or ask the community a question.